Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Labutes IR4.31K FollowersFollow5ShareSavePlay(13min)CommentsSummaryPfizer offers a 6.3% yield, but its high dividend reflects weak growth prospects and looming patent cliffs.PFE’s dividend is currently covered by cash flow, but payout ratios are stretched, and sustainability is questionable beyond 2027 without new revenue streams.Recent acquisitions, notably Metsera, increase leverage and are dilutive near-term but aim to offset $17–18B annual patent expirations by 2028.While the dividend may hold for 3–4 quarters, a 20–30% cut is possible if pipeline drugs or cost savings fail to offset revenue declines. Massimo Giachetti/iStock Editorial via Getty Images While I usually focus my research on the financial sector, for my personal retirement portfolio, I also look for income opportunities across other sectors to have a more balanced and diversified stock portfolio. In the past, IThis article was written byLabutes IR4.31K FollowersFollowLabutes IR is a Fund Manager/Analyst specialized in the financial sector, with more than 18 years of experience in the financial markets. I have worked at several type of institutions in the industry, always at the buy side and related to portfolio management. Associated with the existing author The Outsider.Analyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.